CBOE vs CME Stock Comparison
CBOE currently leads CME in this stock comparison, with AIQ scores of 58 vs 57. The clearest difference is balanced, while CME has the stronger risk resilience profile.
What is the main difference between CBOE and CME?
CBOE leads the current stock comparison as Cboe Global Markets, Inc., with the clearest separation coming from balanced and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Cboe Global Markets, Inc. vs CME Group Inc.
CBOE leads
CBOE leads by 1 AIQ points, but the lead has narrowed from 4 points over 30 sessions. Wall Street currently favors CME on target upside.
Fragile: 1 of 6 evidence groups support CBOE, its lead is narrowing, and its signal state is cleanly positive.
Cboe Global Markets, Inc.
CME Group Inc.
The Algovestiq AIQ Score currently favors CBOE over CME, 58 versus 57 as of Oct 31, 2026. CBOE also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors CME. 1 of 6 covered evidence groups favor CBOE today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 1 points. CBOE lead: Weakening — the AIQ differential moved from 4 to 1 points over 30 sessions.
Compare Cboe Global Markets, Inc. and CME Group Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Total return with distributions reinvested, from daily closes.
Total return comparison
Growth of $10,000, distributions reinvested
Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.
Compare CBOE and CME against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Risk Resilience49 vs 53CME +4
- Momentum80 vs 78Even
- Quality75 vs 74Even
- Value26 vs 25Even
1 of 6 evidence groups favor CBOE. Neither name separates cleanly on the covered dimensions.
What changed since the last close
Latest scored session 2026-10-30, compared against the prior scored session 2026-10-29.
No factor moved materially.
No signal started or stopped since the prior session; its 4 active signals are unchanged.
No factor moved materially.
No signal started or stopped since the prior session; its 3 active signals are unchanged.
CBOE's lead was unchanged in the latest session.
Deeper signal detail for each name lives on its own signals page — CBOE and CME both carry a full feed there.
The central trade-off
CBOE (Cboe Global Markets, Inc.): the stronger current systematic profile.
CME (CME Group Inc.): the counter-case, on risk resilience, fundamentals, analyst expectations.
The AIQ Score and Wall Street therefore point in different directions on this pair.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
CBOECBOE on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
EvenGrowth figures are not covered for both names.
Value
EvenThe two are level on Value.
Momentum
EvenThe two are level on Momentum.
Lower downside
CMECME on Risk Resilience, by 4 points.
Analyst upside
CMECME on implied upside to the consensus price target.
AIQ vs Wall Street
The model and the Street disagree here: AIQ favors CBOE, analyst targets favor CME. That disagreement is the most useful thing on this page.
| Measure | CBOE | CME | Note |
|---|---|---|---|
| Implied upside to target | -0.5% | +3.8% | CME has more room |
| Target dispersion | +57.5% | +34% | Lower is tighter analyst agreement |
| Consensus | Hold | Buy | Context, not a primary driver |
| Analysts covering | 7 | 8 | Higher coverage generally improves confidence |
The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
Dividend growth
| Dividend metric | CBOE | CME |
|---|---|---|
| 5Y dividend CAGR | 11.60% | 8.02% |
| 2020 regular DPS | $1.560 | $3.400 |
| 2025 regular DPS | $2.700 | $5.000 |
| Years increased | 5 | 5 |
| No cut in window | Yes | Yes |
| Cohort rank | #67 | not ranked |
CBOE grew its split-adjusted regular dividend faster over 2020–2025 — 11.60% a year against CME's 8.02%. Neither company reduced its regular dividend in any year of the window.
Yield and payout ratio shown elsewhere on this page are current values, not part of the study window.
Split-adjusted regular dividends per share, 2020–2025, excluding special dividends. Research as of Sep 19, 2026.
AIQ Agreement Matrix
1 of 6 covered evidence groups favor CBOE. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | Even | 58 vs 57 |
| Fundamentals | CMEon balance | revenue growth 13.4% vs 1.8%; EPS growth -8.4% vs 1.4%; TTM ROE 25.7% vs 16.2%; gross margin 52.3% vs 84.3%; operating margin 35.2% vs 65.7% — CME takes 3 of 5 decided legs, not all of them |
| Valuation | Even | Value 26 vs 25 |
| Technicals | CBOE | Price vs 50-day 14.5% vs 8.6%; vs 200-day 9.8% vs 5% |
| Risk Resilience | CME | Risk Resilience 49 vs 53 |
| Analyst expectations | CME | Target upside -0.5% vs 3.8% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of CBOE and CME and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is narrow at 1 points. (argues the conclusion is provisional)
- Only 1 of 6 covered evidence groups agree. (argues the conclusion is provisional)
- The leader's advantage has been narrowing. (argues the conclusion is provisional)
- The lead has been steady session to session. (supports the conclusion holding)
- The leader's signal state is cleanly positive. (supports the conclusion holding)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on CBOE.
How the comparison changed
120 daily snapshots · Jul 1 – Oct 30CBOE lead: Weakening — the AIQ differential moved from 4 to 1 points over 30 sessions.
- Today
- CBOE +1
- 58 vs 57
- 7 sessions ago
- CBOE +1
- 61 vs 60
- 30 sessions ago
- CBOE +4
- 60 vs 56
- 90 sessions ago
- CME +1
- 59 vs 60
The lead changed hands 2 times in this window, most recently on Sep 30 when CBOE moved ahead of CME.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
4 bullish / 0 bearish
Only CBOE
- Golden Cross Active — bullish, trend, long horizon (0.40%)
- Uptrend Structure Active — bullish, trend, long horizon
2 bullish / 1 bearish, conflicted
Only CME
- Death Cross Active — bearish, trend, long horizon (0.29%)
Both carry 2 more signals that do not separate them: EMA Ribbon Expansion Bullish, MACD Bullish Crossover.
CME is conflicted, so the timing case there is weaker than the score alone suggests.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +6.77%, AIQ 0 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +2.27%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1CME's Death Cross Active resolves — a bearish trend rule currently active against it.
- 2CBOE's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict.
- 3The narrowing continues — the lead has already given back 3 points over 30 sessions, and a further 1-point move would eliminate CBOE's advantage entirely.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
CME leads on balance| Metric | CBOE | CME |
|---|---|---|
| Revenue growth (YoY) | 13.4% | 1.8% |
| EPS growth (YoY) | -8.4% | 1.4% |
| Gross margin | 52.3% | 84.3% |
| Operating margin | 35.2% | 65.7% |
| Return on equity (TTM) | 25.7% | 16.2% |
| Debt to equity | 0.28 | 0.13 |
Performance
CBOE leads 5 of 6 windows| Metric | CBOE | CME |
|---|---|---|
| 1 week (5 sessions) | 0.5% | -0.6% |
| 1 month (20 sessions) | 16.4% | 12.2% |
| 3 months (63 sessions) | 8.1% | 10% |
| 6 months (126 sessions) | 4.8% | 2.4% |
| Year to date | 27.7% | 7.7% |
| 1 year (252 sessions) | 34.2% | 9.1% |
Technicals
CBOE has the stronger structure| Metric | CBOE | CME |
|---|---|---|
| RSI (14) | 62.3 | 66.1 |
| ADX (14) | 32 | 30.6 |
| Price vs 50-day | 14.5% | 8.6% |
| Price vs 200-day | 9.8% | 5% |
| Volatility (1M, annualized) | 38.4% | 27.6% |
Risk
CME is the more resilient| Metric | CBOE | CME |
|---|---|---|
| Beta | -0.42 | -0.36 |
| Sharpe ratio | 0.9 | 0.37 |
| Sortino ratio | 1.21 | 0.51 |
| Max drawdown | -36.9% | -33% |
| Current drawdown | -12.6% | -9.9% |
| Annualized volatility | 35.9% | 25.1% |
| Value at risk (95%) | -3.2% | -2.9% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, CBOE or CME?
On the Algovestiq AIQ Score, CBOE is the stronger of the two as of Oct 31, 2026, scoring 58 against CME's 57. The edge comes from its factor profile. CME is not without a case — it holds the better risk resilience profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is CBOE or CME the better buy right now?
CBOE carries the stronger systematic profile as of Oct 31, 2026, and the comparison is rated Fragile — 1 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 1 points. Treat the lead as provisional.
Why does the AIQ Score favor CBOE over CME?
The composite weights Quality, Value, Momentum and Risk Resilience. CME leads Risk Resilience by 4 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, CBOE or CME?
Analyst price targets imply -0.5% upside for CBOE and +3.8% for CME, so the Street currently favors CME. That points the opposite way to the AIQ Score, which favors CBOE. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, CBOE or CME?
Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, CBOE or CME?
Growth figures are not covered for both names. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, CBOE or CME?
The two are level on Momentum. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, CBOE or CME?
CME is the more resilient of the two, so the other name carries the higher downside risk. CME on Risk Resilience, by 4 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is CBOE more profitable than CME?
The profitability evidence is mixed: gross margin 52.3% vs 84.3%; operating margin 35.2% vs 65.7%; ttm roe 25.7% vs 16.2%. CBOE leads on one measure and CME on two measures, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is CBOE's lead over CME getting stronger or weaker?
CBOE lead: Weakening — the AIQ differential moved from 4 to 1 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-07-01 and 2026-10-30. The lead has changed hands 2 times in that window, most recently on 2026-09-30, when CBOE moved ahead of CME.
What would change the CBOE vs CME verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: CME's Death Cross Active resolves — a bearish trend rule currently active against it; CBOE's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict; the narrowing continues — the lead has already given back 3 points over 30 sessions, and a further 1-point move would eliminate CBOE's advantage entirely.
What do the current signals say about CBOE and CME?
CBOE: 4 bullish / 0 bearish. CME: 2 bullish / 1 bearish, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on CBOE is Golden Cross Active (bullish, long horizon). On CME it is Death Cross Active (bearish, long horizon).
Compare CBOE and CME with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.